Reduced risk of disease during postsecondary dengue virus infections. - sprookjes - yvandenbroek - TriplyDB

Reduced risk of disease during postsecondary dengue virus infections.

Reduced risk of disease during postsecondary dengue virus infections.

http://www.wikidata.org/entity/Q37109553

about

Epidemiological risk factors associated with high global frequency of inapparent dengue virus infections Dengue Virus Envelope Dimer Epitope Monoclonal Antibodies Isolated from Dengue Patients Are Protective against Zika Virus Benefits and risks of the Sanofi-Pasteur dengue vaccine: Modeling optimal deployment Incomplete Protection against Dengue Virus Type 2 Re-infection in Peru Dengue: knowledge gaps, unmet needs, and research priorities Epidemiological Characteristics of Dengue Disease in Latin America and in the Caribbean: A Systematic Review of the Literature In a randomized trial, the live attenuated tetravalent dengue vaccine TV003 is well-tolerated and highly immunogenic in subjects with flavivirus exposure prior to vaccination Disease Burden of Dengue in the Philippines: Adjusting for Underreporting by Comparing Active and Passive Dengue Surveillance in Punta Princesa, Cebu City Cost-Effectiveness of Dengue Vaccination Programs in Brazil Time-varying, serotype-specific force of infection of dengue virus.Immune correlates for dengue vaccine development Dengue serotype cross-reactive, anti-e protein antibodies confound specific immune memory for 1 year after infection.Seroprevalence of neutralizing antibodies against dengue virus in two localities in the state of Morelos, Mexico Sequential dengue virus infections detected in active and passive surveillance programs in Thailand, 1994-2010.Preexisting neutralizing antibody responses distinguish clinically inapparent and apparent dengue virus infections in a Sri Lankan pediatric cohort Complexity of Neutralizing Antibodies against Multiple Dengue Virus Serotypes after Heterotypic Immunization and Secondary Infection Revealed by In-Depth Analysis of Cross-Reactive Antibodies Identification of clinical factors associated with severe dengue among Thai adults: a prospective study.Peridomestic Infection as a Determining Factor of Dengue Transmission.Incidence of Dengue Virus Infection in Adults and Children in a Prospective Longitudinal Cohort in the Philippines.The Epidemiology, Virology and Clinical Findings of Dengue Virus Infections in a Cohort of Indonesian Adults in Western Java Safety and Immunogenicity of a Live Attenuated Tetravalent Dengue Vaccine Candidate in Flavivirus-Naive Adults: A Randomized, Double-Blinded Phase 1 Clinical Trial.The Dengue Vaccine Dilemma: Balancing the Individual and Population Risks and Benefits.Neutralizing antibody titers against dengue virus correlate with protection from symptomatic infection in a longitudinal cohort.Dengue Virus (DENV) Neutralizing Antibody Kinetics in Children After Symptomatic Primary and Postprimary DENV Infection.Development of TV003/TV005, a single dose, highly immunogenic live attenuated dengue vaccine; what makes this vaccine different from the Sanofi-Pasteur CYD™ vaccine?Low antibody titers 5 years after vaccination with the CYD-TDV dengue vaccine in both pre-immune and naïve vaccinees Dengue Dynamics and Vaccine Cost-Effectiveness Analysis in the Philippines.Immune correlates of protection for dengue: State of the art and research agenda.Complexity of Human Antibody Response to Dengue Virus: Implication for Vaccine Development.Characterization of Dengue Virus Infections Among Febrile Children Clinically Diagnosed With a Non-Dengue Illness, Managua, Nicaragua.Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination? The Path to a Dengue Vaccine: Learning from Human Natural Dengue Infection Studies and Vaccine Trials.Cross-reactive antibodies enhance live attenuated virus infection for increased immunogenicity.Immune status alters the probability of apparent illness due to dengue virus infection: Evidence from a pooled analysis across multiple cohort and cluster studies.Dengue vaccine: hypotheses to understand CYD-TDV-induced protection.Dengue infection.Live attenuated vaccine: the first clinically approved dengue vaccine?Dengue Fever Surveillance in India Using Text Mining in Public Media.Dengue virus infection-enhancement activity in neutralizing antibodies of healthy adults before dengue season as determined by using FcγR-expressing cells.Neutralization of antibody-enhanced dengue infection by VIS513, a pan serotype reactive monoclonal antibody targeting domain III of the dengue E protein.Immune Responses to Dengue and Zika Viruses-Guidance for T Cell Vaccine Development.

P2860

Q21131163-164F5214-CB64-43F3-98F1-5EE80B0996E1 Q26247258-E0360B50-576C-4FD4-B321-DE8749B06DA6 Q26746185-058D0B03-A995-49A3-99D1-EAFCCB6904B2 Q28550030-8BE139DF-DF34-4EC3-9231-8B381B964850 Q28729764-F724B6B5-7472-4125-9A81-284CFF3F7EAA Q29994646-8C0E3F2F-3352-41FD-9546-79C6D56E50A7 Q30250977-43457D31-5BA5-4FB1-AD5C-D1CCA352B6CE Q33567787-59BF2F84-07CB-4F99-BA2F-4BCBB0688722 Q33636857-BE0B49B4-66F8-4451-BB3D-6670315240D4 Q33854218-0A6BDD32-B43B-45EF-B98E-D43CB117D62C Q33924674-4E17C3DC-3C62-4ED3-914E-0493245C744F Q34042859-28F17C3D-F18D-4C8D-A6D8-915014AF6C05 Q34496118-379D3773-5CEB-47F0-AF25-601F95AB15B2 Q35211928-1419B470-7529-42CD-ACF5-D3879C6A2B21 Q35221318-7CCBDB83-D55F-41B9-9B0A-A2646E92AA8A Q35758626-FDD69527-F09A-4D86-A528-AA40053FB15D Q35807844-A6E89521-1E7F-4EE0-B286-41AF1322387F Q35869778-BE8FAE46-2D01-439E-8467-CC103F5A7A40 Q35914608-6F0ABE9E-5754-49D8-A0AC-348696553390 Q35922560-2392D8F7-BC36-4888-A4BA-1A7C63CB7B61 Q36024479-36FDCAAE-07AC-4F86-9814-30BF70D570BF Q36206719-0A9C55D6-9A45-4E2F-BF07-29D02C75413C Q36498207-56E24A45-BC65-4982-A99E-16D50220CF6B Q36745257-C86458D9-3DDF-4BAC-9051-E1CF2D3057F3 Q37115807-B7C5B375-20B7-488A-8401-BF722F582F11 Q37130999-62E29A7E-4727-40A3-A9CD-9410078BCEEC Q37391237-1762ECE3-3E4F-4ABA-ADB0-05AE5332DB55 Q38652971-A59FF0C9-05DA-420A-9DF6-6E6BE331D78C Q39535403-18DC74AF-6CFD-4533-A403-56EF9ADAEB78 Q40040985-4539F76C-2540-490C-BFEE-2573C4525DF8 Q40047887-E8581C51-A6DC-45DA-9A2F-DFCD9A0612D5 Q40088326-E8A19453-AA35-4A57-8863-2C53F081CB9C Q41929349-AC71FA5F-FD52-44EC-B227-D5F8F0DB8D78 Q42985743-2BE88343-8737-4FE7-9E6A-A51ACE584BB5 Q42996339-EDC44FF6-362C-4847-AB22-DEDFD396BF6F Q42998710-AEC1823F-F4AB-4359-B762-DB820D34506E Q44877095-EDCAAA70-80C6-4456-8C45-A9DF63589F74 Q47555963-D9947298-5FF9-4A68-B79D-1D2BD13FCF66 Q50099498-4C2E6E8D-BC09-403B-89E3-22710DD88662 Q51336680-A59E917B-1B60-4F8F-B9D1-AC48A3FABC34

P2860

Reduced risk of disease during postsecondary dengue virus infections.

http://www.wikidata.org/entity/Q37109553

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 17 June 2013

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

Reduced risk of disease during postsecondary dengue virus infections.

@en

Reduced risk of disease during postsecondary dengue virus infections.

@nl

type

label

Reduced risk of disease during postsecondary dengue virus infections.

@en

Reduced risk of disease during postsecondary dengue virus infections.

@nl

prefLabel

Reduced risk of disease during postsecondary dengue virus infections.

@en

Reduced risk of disease during postsecondary dengue virus infections.

@nl

P1433

Q37109553-19AAEF2F-4700-47BF-868C-203DCE17FD30

P1476

Q37109553-E0D6ADED-E29C-4211-B475-DF64FEEF0062

P2093

Q37109553-02CFBA42-5E2E-4FC4-ACBD-3799638CBD31

Q37109553-1EA38B78-B6CD-4423-828F-0A449ADA0AFC

Q37109553-70A7DB41-EC94-4971-95DD-2D139E2B8F5F

Q37109553-7BD91005-9F33-4C79-9E8E-192520C2E259

Q37109553-BDAD272E-E1B2-4BED-AB03-CDFE315D87AE

Q37109553-DCCC63C6-7510-423C-AB5E-ABB89093DCCB

Q37109553-FCE3F0C6-5F15-474C-A3CC-8D30FEC33CDD

P2860

Q37109553-03B5A805-0C5E-4B05-A721-34C0A214D5FF

Q37109553-146D1121-6EC3-4C97-98F9-DE7B9EA6016E

Q37109553-15AD8BC7-FC5C-4C9A-B7D0-58CC53AA840B

Q37109553-1758EC4B-2099-4BF0-9465-DFD816900B55

Q37109553-17BA61CD-29ED-4F05-A4D7-6B7C600AF013

Q37109553-188FC820-FFE5-40DA-91B4-C89776BBBC98

Q37109553-1C298C57-5990-450F-B13D-D6BD71A7DA3D

Q37109553-26C3E35A-625B-4900-8D15-BB9C022F968A

Q37109553-2EA9CB97-06FC-4726-B71E-DC97731E0079

Q37109553-2FEC791B-A979-4166-A751-EC741F5E54DF

P304

Q37109553-866E399A-8919-4F4D-97DC-23AE4DA12F4B

P31

Q37109553-70AA7045-CE53-430F-97CC-2FC6DEB5ECF0

P356

Q37109553-C236B678-E101-4038-9689-04B61AB57318

P407

Q37109553-9CB50AA9-C431-42D6-8D81-982EDAFFD5A8

P433

Q37109553-5448C0CC-A9BF-445D-AADC-91A0E579193F

P478

Q37109553-236D9ECA-FA52-4107-ABFE-9A49BCAECFB9

P50

Q37109553-447F4E26-47EB-4D19-A918-EA8D12376D3D

Q37109553-B3367321-A7EA-45C4-B78A-260F8DF55E90

P5008

Q37109553-38DB93B3-3B85-4969-86AB-90D193F9E3C8

P577

Q37109553-5A8C36C8-F3B4-4EEC-90FE-DB66DA95EFEC

P5875

Q37109553-ADCBA692-4E94-42D0-8EEF-346DDD0BB7CC

P698

Q37109553-B0E6439F-E9F4-431A-BDA6-04C2238806D7

P921

Q37109553-9CD4B702-BCD8-4A4C-96E2-D4DF246D2944

P932

Q37109553-6BBF065B-BDA6-45E4-AE91-82B5BB59375E

P356

P1433

The Journal of Infectious Diseases

P1476

Reduced risk of disease during postsecondary dengue virus infections.

@en

P2093

Amy C Morrison

http://www.w3.org/2001/XMLSchema#string

Brett M Forshey

http://www.w3.org/2001/XMLSchema#string

Claudio Rocha

http://www.w3.org/2001/XMLSchema#string

Eric S Halsey

http://www.w3.org/2001/XMLSchema#string

Sandra Olkowski

http://www.w3.org/2001/XMLSchema#string

Steven T Stoddard

http://www.w3.org/2001/XMLSchema#string

Tadeusz J Kochel

http://www.w3.org/2001/XMLSchema#string

P2860

Arboviral etiologies of acute febrile illnesses in Western South America, 2000-2007

Rapid detection and typing of dengue viruses from clinical samples by using reverse transcriptase-polymerase chain reaction

Observations related to pathogensis of dengue hemorrhagic fever. VI. Hypotheses and discussion

Dynamic effects of antibody-dependent enhancement on the fitness of viruses

The effect of antibody-dependent enhancement on the transmission dynamics and persistence of multiple-strain pathogens

Ecological and immunological determinants of dengue epidemics

Cross-protective immunity can account for the alternating epidemic pattern of dengue virus serotypes circulating in Bangkok

Dengue viruses and mononuclear phagocytes. I. Infection enhancement by non-neutralizing antibody

Structural Insights into the Mechanisms of Antibody-Mediated Neutralization of Flavivirus Infection: Implications for Vaccine Development

P304

1026-1033

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1093/INFDIS/JIT273

http://www.w3.org/2001/XMLSchema#string

P407

P433

6

http://www.w3.org/2001/XMLSchema#string

P478

208

http://www.w3.org/2001/XMLSchema#string

P50

Stalin Vilcarromero

P5008

P577

2013-06-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

239945910

http://www.w3.org/2001/XMLSchema#string

P698

23776195

http://www.w3.org/2001/XMLSchema#string

P921

P932

3749012

http://www.w3.org/2001/XMLSchema#string